Sub Categories

Search

Newsletter

Apelin-12 Chemiluminescent EIA Kit Maximize

Apelin-12 Chemiluminescent EIA Kit

Apelin-12 Chemiluminescent EIA Kit (Human, Bovine, Rat, Mouse)(CEK-057-23) is intended for quantitative measurement of apelin 12 in-vitro.

More details

CEK-057-23

96 wells

£ 480.00

Apelin-12 Chemiluminescent EIA Kit

Specificity : Human, Mouse, Rat, Bovine
Sensitivity : 13.7 pg/ml
Linear Range: 13.7-151 pg/ml
Range: 0-10000 pg/ml
Size: 96 tests

Reagents Supplied:
- 96 well immunoplate (1 plate)
- 20x assay buffer concentrate (50ml)
- Standard peptide (1 vial).
- Primary antibody (rabbit anti-peptide IgG) (1 vial).
- Positive control (1 vial).
- Acetate plate sealer (APS), (3 pieces)
- Streptavidin-horseradish peroxidase (SA-HRP) (30μl)
- Substrate solution A (7ml)
- Substrate solution B (7ml)
- Biotinylated peptide (1 vial).
- General protocol (1 book).
- Assay diagram (1 sheet).

Intended Use:
Apelin 12 chemiluminescent EIA (human, bovine, rat, mouse) is a method for quantitatively measuring amounts of human, rat, mouse or bovine apelin-12 in plasma, serum, culture media, urine, CSF and tissue homogenate and any biological fluid samples

Assay Principle:
1. Microwell plate has been pre-coated with secondary antibody and also the non-specific binding sites have been blocked.
2. Secondary antibody is able to bind with the Fc fragment of the primary antibody, the Fab segment is competitively bound by both biotinylated peptides and the peptide standard or the targeted peptide in samples.
3. Biotinylated peptide can then interact with the SA-HRP, which then catalyzes the substrate solution.
4. Luminescence intensity is directly proportional to the amount of biotinylated peptide-SA-HRP complex but inversely proportional to the amount of the peptide in standard solutions or samples.
5. Unknown concentration in samples can then be determined by extrapolation from a standard curve.

Cross Reactivity:
Apelin-12 (Human) 100%.
Apelin-36 (Human, Rat) 100%.
Apelin-13 (Human, Rat) 100%.
Alpha-ANP  0%.
ADM-52 (Human)  0%.
ANP (25-56) (N-ANP)  0%.
CNP-22 0%.
ET-1  (Human) 0%.
BNP-32 (Human)  0%.
Bradykinin  0%.
Ghrelin  (Human) 0%.

Background:
Apelin 12 functions as a mediator of the cardiovascular control, which includes blood flow and blood pressure and is also an endogenous ligand for the G-protein-coupled APJ receptor. It is also a potent stimulators of cardiac contractility, playing a vital part in cardiac tissue remodelling, it is widely expressed in various organs such as the heart, gastrointestinal tract, kidney, lung, adipose tissue, endothelium, brain, adrenal glands and human plasma. Its levels are increased in left ventricles of patients with chronic heart failure, making it a potent stimulator of cardiac contractility, playing a vital part in cardiac tissue re-modeling.

References
1. Eur Heart J. (2006) 27 (2): 222-6. Reduced apelin levels in lone atrial fibrillation. Ellinor et al.
2. J Am Coll Cardiol. (2008) 52 (11): 908-13. Vascular effects of apelin in vivo in man. Japp et al.
3. Atherosclerosis. (2009) 204 (1): 222-8. LDL-cholesterol lowering increases plasma apelin in isolated hypercholesterolemia. Tasci et al.
4. Am J Pathol. (2007) 171 (5): 1705-12. Requirement of Apelin-Apelin Receptor System for Oxidative Stress-Linked Atherosclerosis. Hashimoto et al.
5. Am J Physiol Endocrinol Metab. (2007) 293 (6): 1590-6. HIF-1 regulates hypoxia- and insulin-induced expression of apelin in adipocytes. Glassford et al.
6. Cell Metab. (2008) 8 (5): 437-45. Apelin Stimulates Glucose Utilization in Normal and Obese Insulin-Resistant Mice. Dray et al.
7. Am J Nephrol. (2007) 27 (1): 1-6. Evidence for Decreased Circulating Apelin beyond Heart Involvement in Uremic Cardiomyopathy. Codognotto et al.
8. Acta Paediatr. (2007) 96 (12): 1751-4. Circulating apelin concentrations in mother/infant pairs at term. Malamitsi-Puchner et al.
9. J Mol Cell Cardiol. (2006) 41 (5): 798-806. Down-regulation of cardiac apelin system in hypertrophied and failing hearts: Possible role of angiotensin II-angiotensin type 1 receptor system. Iwanaga et al.
10. Endocrinology. (2005) 146 (4): 1764-71. Apelin, a newly identified adipokine up-regulated by insulin and obesity. Boucher et al.
11. Eur J Heart Fail. (2007) 9 (3): 306-9. Cardiac resynchronization therapy increases plasma levels of the endogenous inotrope apelin. Francia et al.
12. Regul Pept. (2008) 150 (1-3): 33-7. The transcriptional co-activator PGC-1alpha up regulates apelin in human and mouse adipocytes. Mazzucotelli et al.

Special Offers